1 – 15 of 15
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hyaluronic Acid-Conjugated Thermoresponsive Polymer-Based Bioformulation Enhanced Wound Healing and Gut Barrier Repair of a TNBS-Induced Colitis Injury Ex Vivo Model in a Dynamic Perfusion Device
(
- Contribution to journal › Article
-
Mark
Histologic Remission in Inflammatory Bowel Disease and Female Fertility : A Nationwide Study
2024) In Gastroenterology(
- Contribution to journal › Article
- 2023
-
Mark
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations
(
- Contribution to journal › Article
-
Mark
Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients : comparison of retrospective cohorts
(
- Contribution to journal › Article
- 2022
-
Mark
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes : A nationwide study
(
- Contribution to journal › Article
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Letter: to switch or not to switch, that is the question—author's reply
(
- Contribution to journal › Letter
-
Mark
Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply
2022) In Alimentary Pharmacology and Therapeutics(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2020
-
Mark
Mycophenolate mofetil for systemic sclerosis : Drug exposure exhibits considerable inter-individual variation-a prospective, observational study
(
- Contribution to journal › Article
- 2018
-
Mark
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
(
- Contribution to journal › Article
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2017
-
Mark
Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile
(
- Contribution to journal › Article
-
Mark
Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
(
- Contribution to journal › Article
- 2013
-
Mark
IRF4 Transcription-Factor-Dependent CD103(+)CD11b(+) Dendritic Cells Drive Mucosal T Helper 17 Cell Differentiation.
(
- Contribution to journal › Article